Lakewood-Amedex Biotherapeutics Inc. (Nasdaq:
$LABT ) reported positive Minimum Inhibitory Concentration (MIC) data from in vitro testing of its lead clinical candidate, Nu-3, against recent clinical isolates from infected diabetic foot ulcers. Nu-3, a topically formulated Bisphosphocin®, is currently being investigated in a Phase 2a clinical trial in mildly infected diabetic foot ulcers (iDFU), with topline data expected in the first quarter of 2027.
Lakewood-Amedex Biotherapeutics Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/lakewood-amedex-biotherapeutics-inc-1
In this in vitro study, Nu-3 showed consistent activity against all organisms tested, including the drug-resistant strains:
• The isolates were collected within the last 3 years from patients with diabetic foot infections at 14 U.S. medical centers
• Pathogens tested included resistant and susceptible Staphylococcus aureus (MRSA and MSSA) and resistant and susceptible Enterococcus faecalis (VRE and VSE)
• Antibacterial activity of Nu-3 was not affected by the drug resistance phenotype
• MIC values were 2 to 8 times lower than the doses planned for clinical trials
Regarding the isolates, Kelvin Cooper, Ph.D., Chief Executive Officer of Lakewood-Amedex Biotherapeutics, said: "Importantly, the data show clear and positive cidal activity against specific microbes isolated from real world patients. These microbes are a clear threat to patients with iDFU, and more broadly represent the global threat of antibiotic resistance."
Read the full release: https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-announces-positive-data-against-recent-clinical-isolates-from-infected-diabetic-foot-ulcers-302890943.html
Of the 830 million people in the world with diabetes, about one third will develop a diabetic foot ulcer, close to 50% of those ulcers become infected, and 15% to 20% of infected ulcers involve resistant pathogens, primarily MRSA. Results in the new testing fell within the range of earlier assays covering 285 clinical isolates across 15 species, and S. aureus (ATCC 29213) and E. faecalis (ATCC 29212) served as control strains.
Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials, the Bisphosphocin® class, to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.
Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com.
B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer.
Lakewood-Amedex Biotherapeutics Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/lakewood-amedex-biotherapeutics-inc-1
In this in vitro study, Nu-3 showed consistent activity against all organisms tested, including the drug-resistant strains:
• The isolates were collected within the last 3 years from patients with diabetic foot infections at 14 U.S. medical centers
• Pathogens tested included resistant and susceptible Staphylococcus aureus (MRSA and MSSA) and resistant and susceptible Enterococcus faecalis (VRE and VSE)
• Antibacterial activity of Nu-3 was not affected by the drug resistance phenotype
• MIC values were 2 to 8 times lower than the doses planned for clinical trials
Regarding the isolates, Kelvin Cooper, Ph.D., Chief Executive Officer of Lakewood-Amedex Biotherapeutics, said: "Importantly, the data show clear and positive cidal activity against specific microbes isolated from real world patients. These microbes are a clear threat to patients with iDFU, and more broadly represent the global threat of antibiotic resistance."
Read the full release: https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-announces-positive-data-against-recent-clinical-isolates-from-infected-diabetic-foot-ulcers-302890943.html
Of the 830 million people in the world with diabetes, about one third will develop a diabetic foot ulcer, close to 50% of those ulcers become infected, and 15% to 20% of infected ulcers involve resistant pathogens, primarily MRSA. Results in the new testing fell within the range of earlier assays covering 285 clinical isolates across 15 species, and S. aureus (ATCC 29213) and E. faecalis (ATCC 29212) served as control strains.
Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials, the Bisphosphocin® class, to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.
Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com.
B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer.
$SCYX,
$XBI $SPRO